Cargando…

Truth in DAIR: Duration of Therapy and the Use of Quinolone/Rifampin-Based Regimens After Debridement and Implant Retention for Periprosthetic Joint Infections

BACKGROUND: The optimal duration of antibiotic therapy after debridement and implant retention (DAIR) for periprosthetic joint infections (PJIs) is debated. Furthermore, the best antibiotic regimens for staphylococcal PJI are also unclear. In this study, we evaluated the impact of antibiotic therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Tai, Don Bambino Geno, Berbari, Elie F, Suh, Gina A, Lahr, Brian D, Abdel, Matthew P, Tande, Aaron J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9439576/
https://www.ncbi.nlm.nih.gov/pubmed/36072695
http://dx.doi.org/10.1093/ofid/ofac363
_version_ 1784782095781986304
author Tai, Don Bambino Geno
Berbari, Elie F
Suh, Gina A
Lahr, Brian D
Abdel, Matthew P
Tande, Aaron J
author_facet Tai, Don Bambino Geno
Berbari, Elie F
Suh, Gina A
Lahr, Brian D
Abdel, Matthew P
Tande, Aaron J
author_sort Tai, Don Bambino Geno
collection PubMed
description BACKGROUND: The optimal duration of antibiotic therapy after debridement and implant retention (DAIR) for periprosthetic joint infections (PJIs) is debated. Furthermore, the best antibiotic regimens for staphylococcal PJI are also unclear. In this study, we evaluated the impact of antibiotic therapy duration on the risk of failure. We assessed the utility of rifampin-based regimens for staphylococcal PJI managed with DAIR. METHODS: We performed a retrospective cohort study of patients 18 years and older diagnosed with hip and knee PJI who underwent DAIR between January 1, 2008 and 31 December 31, 2018 at Mayo Clinic, USA. The outcome was failure of DAIR. For statistical analysis, joint-stratified Cox regression models adjusted for age, sinus tract, symptom duration, and primary/revision arthroplasty were performed. RESULTS: We examined 247 cases of PJI with a median follow-up of 4.4 years (interquartile range [IQR], 2.3–7) after DAIR. The estimated 5-year cumulative incidence of failure was 28.1% (n = 65). There was no association between the duration of intravenous (IV) antibiotics (median 42 days; IQR, 38–42) and treatment failure (P = .119). A shorter duration of subsequent oral antibiotic therapy was associated with a higher risk of failure (P = .005; eg, 90-day vs 1-year duration; hazard ratio [HR], 3.50; 95% confidence interval [CI], 1.48–8.25). For staphylococcal knee PJI, both the use and longer duration of a rifampin-based regimen were associated with a lower risk of failure (both P = .025). There was no significant association between fluoroquinolone (FQ) use and failure (HR, 0.62; 95% CI, .31–1.24; P = .172). CONCLUSIONS: The duration of initial IV antibiotic therapy did not correlate with treatment failure in this cohort of patients. Rifampin use is recommended for staphylococcal knee PJI. There was no apparent benefit of FQ use in staphylococcal PJI.
format Online
Article
Text
id pubmed-9439576
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-94395762022-09-06 Truth in DAIR: Duration of Therapy and the Use of Quinolone/Rifampin-Based Regimens After Debridement and Implant Retention for Periprosthetic Joint Infections Tai, Don Bambino Geno Berbari, Elie F Suh, Gina A Lahr, Brian D Abdel, Matthew P Tande, Aaron J Open Forum Infect Dis Major Article BACKGROUND: The optimal duration of antibiotic therapy after debridement and implant retention (DAIR) for periprosthetic joint infections (PJIs) is debated. Furthermore, the best antibiotic regimens for staphylococcal PJI are also unclear. In this study, we evaluated the impact of antibiotic therapy duration on the risk of failure. We assessed the utility of rifampin-based regimens for staphylococcal PJI managed with DAIR. METHODS: We performed a retrospective cohort study of patients 18 years and older diagnosed with hip and knee PJI who underwent DAIR between January 1, 2008 and 31 December 31, 2018 at Mayo Clinic, USA. The outcome was failure of DAIR. For statistical analysis, joint-stratified Cox regression models adjusted for age, sinus tract, symptom duration, and primary/revision arthroplasty were performed. RESULTS: We examined 247 cases of PJI with a median follow-up of 4.4 years (interquartile range [IQR], 2.3–7) after DAIR. The estimated 5-year cumulative incidence of failure was 28.1% (n = 65). There was no association between the duration of intravenous (IV) antibiotics (median 42 days; IQR, 38–42) and treatment failure (P = .119). A shorter duration of subsequent oral antibiotic therapy was associated with a higher risk of failure (P = .005; eg, 90-day vs 1-year duration; hazard ratio [HR], 3.50; 95% confidence interval [CI], 1.48–8.25). For staphylococcal knee PJI, both the use and longer duration of a rifampin-based regimen were associated with a lower risk of failure (both P = .025). There was no significant association between fluoroquinolone (FQ) use and failure (HR, 0.62; 95% CI, .31–1.24; P = .172). CONCLUSIONS: The duration of initial IV antibiotic therapy did not correlate with treatment failure in this cohort of patients. Rifampin use is recommended for staphylococcal knee PJI. There was no apparent benefit of FQ use in staphylococcal PJI. Oxford University Press 2022-07-25 /pmc/articles/PMC9439576/ /pubmed/36072695 http://dx.doi.org/10.1093/ofid/ofac363 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Major Article
Tai, Don Bambino Geno
Berbari, Elie F
Suh, Gina A
Lahr, Brian D
Abdel, Matthew P
Tande, Aaron J
Truth in DAIR: Duration of Therapy and the Use of Quinolone/Rifampin-Based Regimens After Debridement and Implant Retention for Periprosthetic Joint Infections
title Truth in DAIR: Duration of Therapy and the Use of Quinolone/Rifampin-Based Regimens After Debridement and Implant Retention for Periprosthetic Joint Infections
title_full Truth in DAIR: Duration of Therapy and the Use of Quinolone/Rifampin-Based Regimens After Debridement and Implant Retention for Periprosthetic Joint Infections
title_fullStr Truth in DAIR: Duration of Therapy and the Use of Quinolone/Rifampin-Based Regimens After Debridement and Implant Retention for Periprosthetic Joint Infections
title_full_unstemmed Truth in DAIR: Duration of Therapy and the Use of Quinolone/Rifampin-Based Regimens After Debridement and Implant Retention for Periprosthetic Joint Infections
title_short Truth in DAIR: Duration of Therapy and the Use of Quinolone/Rifampin-Based Regimens After Debridement and Implant Retention for Periprosthetic Joint Infections
title_sort truth in dair: duration of therapy and the use of quinolone/rifampin-based regimens after debridement and implant retention for periprosthetic joint infections
topic Major Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9439576/
https://www.ncbi.nlm.nih.gov/pubmed/36072695
http://dx.doi.org/10.1093/ofid/ofac363
work_keys_str_mv AT taidonbambinogeno truthindairdurationoftherapyandtheuseofquinolonerifampinbasedregimensafterdebridementandimplantretentionforperiprostheticjointinfections
AT berbarielief truthindairdurationoftherapyandtheuseofquinolonerifampinbasedregimensafterdebridementandimplantretentionforperiprostheticjointinfections
AT suhginaa truthindairdurationoftherapyandtheuseofquinolonerifampinbasedregimensafterdebridementandimplantretentionforperiprostheticjointinfections
AT lahrbriand truthindairdurationoftherapyandtheuseofquinolonerifampinbasedregimensafterdebridementandimplantretentionforperiprostheticjointinfections
AT abdelmatthewp truthindairdurationoftherapyandtheuseofquinolonerifampinbasedregimensafterdebridementandimplantretentionforperiprostheticjointinfections
AT tandeaaronj truthindairdurationoftherapyandtheuseofquinolonerifampinbasedregimensafterdebridementandimplantretentionforperiprostheticjointinfections